Esperion Therapeutics
ESPR
ESPR
152 hedge funds and large institutions have $991M invested in Esperion Therapeutics in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
9% less funds holding
Funds holding: 167 → 152 (-15)
25% less capital invested
Capital invested by funds: $1.32B → $991M (-$333M)
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
Holders
152
Holding in Top 10
4
Calls
$23.3M
Puts
$17.8M
Top Buyers
1 | +$15.4M | |
2 | +$12.9M | |
3 | +$8.94M | |
4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$6.75M |
5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.67M |
Top Sellers
1 | -$72.3M | |
2 | -$6.96M | |
3 | -$6.14M | |
4 |
State Street
Boston,
Massachusetts
|
-$5.52M |
5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$5.44M |